Home > Press > Nanogen Announces Collaboration with Canadian Agencies to Develop Veterinary and Bioterror Diagnostics
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has received project funding from several Canadian agencies, including the Canadian Food Inspection Agency (CFIA). The purpose of the funding and collaborative agreement is to develop diagnostic tools for the detection of natural or potential bioterror threats to livestock, such as foot and mouth disease and avian flu, employing the company's NanoChip® platform.
Nanogen Announces Collaboration with Canadian Agencies to Develop Veterinary and Bioterror Diagnostics
SAN DIEGO, CA | Posted on June 12th, 2007
"Although the majority of our NanoChip® instruments are used in basic research and human clinical diagnostics applications, we have always known that the platform's flexibility confers benefit in other markets, such as veterinary diagnostics and the monitoring of bioterror threats," said Nanogen president and chief operating officer David Ludvigson.
Foot and mouth disease, a viral infection that devastated the beef industry in the United Kingdom in 2001, is a bioterror concern because it is easily transmissible from animal to animal. Economic losses could be enormous - the 2001 epidemic cost an estimated $12 billion, according to a study sponsored by the Wash., D.C.-based Center for Strategic and International Studies. Avian flu poses a similar threat to poultry stocks.
The NanoChip® 400 is the company's second generation automated multiplexing platform, which uses advanced microarray technology for performing pathogen sequence detection and genotyping applications. Multiple samples with multiple targets can be applied to an open and flexible electronic microarray, the NanoChip cartridge, which may be reused until all test sites have been utilized. As the NanoChip arrays are built by users rather than containing pre-determined content, the system provides a simple, fast and cost effective means for performing molecular testing.
The project, titled "Adaptation of Recently Developed DNA Microarrays to NanoChip Microarray Technology for Detection of Agroterrorism Agents" was approved by Defence Research and Development Canada through the CRTI Program (CBRNE [Chemical, Biological, Radiological, and Nuclear] Research and Technology Initiative (CRTI). Financial terms were not disclosed. Additional collaborators include the CFIA's laboratory in Lethbridge, Alberta and the National Center for Foreign Animal Diseases located in Winnipeg, Manitoba.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen's website at http://www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Suzanne Clancy, Corporate Communications, 858-410-4688
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nano-supercapacitors for electric cars July 25th, 2014
New imaging agent provides better picture of the gut July 25th, 2014
Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster: University of Leicester research team unlocks insights into creation of new nano-materials July 25th, 2014
Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014
Nano-sized Chip "Sniffs Out" Explosives Far Better than Trained Dogs: TAU researcher's groundbreaking sensor detects miniscule concentrations of hazardous materials in the air July 23rd, 2014
Tiny laser sensor heightens bomb detection sensitivity July 19th, 2014
Nanotubes boost terahertz detectors: Rice-led project may dramatically improve medical imaging, passenger screening, food inspection June 11th, 2014
Nanotube coating helps shrink mass spectrometers March 25th, 2014
Key Announcements made at TAPPI International Nanotechnology Conference July 7th, 2014
Squid sucker ring teeth material could aid reconstructive surgery, serve as eco-packaging July 2nd, 2014
FDA issues guidance on use of nanotechnology in foods July 1st, 2014
Shaken, not stirred -- mythical god's capsules please! June 26th, 2014
A*STAR and industry form S$200M semiconductor R&D July 25th, 2014
Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014
Haydale and Goodfellow Announce Major Distribution Agreement for Functionalised Graphene Materials July 21st, 2014
SentiMag® Now Available in Australia and New Zealand July 21st, 2014